Who should receive Sandostatin LAR?

Sandostatin LAR treats carcinoid syndrome, vasoactive intestinal peptide secreting adenomas and acromegaly. It is for people who have had successful results from taking immediate-release Sandostatin. Sandostatin LAR is a long-action formulation of Sandostatin. The drug is slowly released in your system and therefore needs be administered only once every 28 days for long-term control of symptoms.

Continue Learning about Endocrine-Metabolic Agent

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.